Former Associated Press journalist and newsroom leader Paul Driscoll has died at the age of 91. Driscoll covered the civil rights movement and 1968 Democratic National Convention protests in Chicago.

Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges.

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder cancer. Using the immunotherapy drug durvalumab before and after surgery reduced the recurrence of operable bladder cancer by a third,

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time patients wait.

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or returning when treated with immunosurpressant drug durvalumab, and were more likely to still be alive two years after treatment.

Flossmoor resident and cancer survivor Ann Jackson launched the Center for Food Equity in Medicine at Flossmoor Community Church.

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety study results prior to the submission of a complete application to support an earlier start to the agency's review.

Bladder cancer is largely a disease of the elderly ... @zklaassen_md on Twitter during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, Fri, May 31 – Tues, June 4, 2024.

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.